CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 93 enrolled
Drug / intervention
Intravenous Infusiondrug
Likely dose
Intravenous levodopa 1.0 to 1.5 mg/kg/hr infused over 2 hours (0930-1130) on a single visit dayAI-extracted
Key inclusion· 3
  • ✓Diagnosis of Parkinson's Disease
  • ✓Age at Parkinson's Disease diagnosis ≥50 years
  • ✓Levodopa treatment for ≥5 years
Key exclusion· 7
  • ✕History of Deep Brain Stimulation
  • ✕Unable to stand for 1-minute intervals or sensory deficits in feet
  • ✕Significant cognitive impairment (Montreal Cognitive Assessment <18)
  • ✕Unstable medical or psychiatric conditions, including hallucinations

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04064294
NCT04064294N/ACompleted
CompareCT.gov

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With Statins

VA Office of Research and Development·observational·Posted Aug 21, 2019·Updated Apr 11, 2025

In Brief

An observational study evaluating Intravenous Infusion for Parkinson Disease and Dyskinesia, Drug-Induced. Completed, enrolled 93 participants across 3 sites.

Detailed Summary

In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease, Dyskinesia, Drug-Induced
CountriesUnited States
CollaboratorsOregon Health and Science University

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedAug 21, 2019
Enrollment StartAug 22, 2019
Primary CompletionMar 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 6.9 years ago

Interventions

Intravenous Infusiondrug

Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.